Aim: To study the impact of Atorvastatin on glycemic parameters in individuals with normal blood sugar levels and those with prediabetes. Materials and Methods: 150 participants were consecutively recruited according to their glycemic status until 50 participants were included in each group:Group A (50 participants): Normoglycemic with normal baseline blood glucose levels.Group B (50 participants): Impaired fasting glucose (IFG) with normal glucose tolerance test (GTT); baseline fasting blood glucose levels between 100-125 mg/dL.Group C (50 participants): Impaired glucose tolerance (IGT); baseline 2-hour post-glucose blood sugar levels between 140-199 mg/dL.HbA1c levels were determined using the ion-exchange HPLC method.Serum glucose levels were measured using the glucose oxidase-peroxidase method in an autoanalyzer.Following a 75g glucose load in 150 ml of water, blood samples were drawn 2 hours later. The blood sample was collected in a sodium fluoride tube, promptly centrifuged, and the plasma was frozen until glucose measurement.Lipid levels were measured using routine enzymatic methods following the protocols of the Lipid Research Clinics. Results: The consistent p-value of <0.001 across all timepoints indicates that these changes were statistically significant, suggesting that higher doses of Atorvastatin might be associated with a greater increase in HbA1c, particularly in participants with pre-existing glucose intolerance.The p-values remained <0.001 across all timepoints, indicating that the increases in FBG were statistically significant, particularly with higher doses of Atorvastatin. This suggests a dose-dependent relationship between Atorvastatin and worsening glycemic control over time. The lipid-lowering efficacy of Atorvastatin, particularly at higher doses, which are associated with greater reductions in Total Cholesterol, LDL-C, and Triglycerides, and a modest increase in HDL-C.The regression analysis presented in this table assesses the relationship between Atorvastatin dose and changes in HbA1c levels. The regression coefficient (β) of -0.034 indicates a statistically significant inverse relationship between Atorvastatin dose and HbA1c change (p=0.002). Conclusion: The study's findings highlight the dual effects of Atorvastatin on lipid and glycemic control. While higher doses of Atorvastatin are more effective in lowering lipid parameters, they are also associated with a greater increase in HbA1c and fasting blood glucose levels, particularly in individuals with impaired glucose metabolism.